https://doi.org/10.4081/reumatismo.2019.1095
Catastrophic antiphospholipid syndrome as a complication of systemic sclerosis
Submitted: 7 February 2018
Accepted: 17 December 2018
Published: 9 July 2019
Accepted: 17 December 2018
Abstract Views: 1228
PDF: 932
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
A 62-year-old man with a history of systemic sclerosis was admitted with diffuse alveolar hemorrhage and acute kidney injury without clinical data suggestive of glomerulonephritis. Laboratory tests showed anemia, leukocytosis with neutrophilia, thrombocytopenia, elevated serum creatinine and metabolic acidosis. Antinuclear antibodies were positive at a titer of 1/640 (speckled, 1/160; nucleolar, 1/320) while rheumatoid factor, anti Scl-70, anti-centromere, anti-neutrophil cytoplasmic antibody and anti-glomerular basement membrane antibodies were negative and serum complement levels were within normal range. During the following days, the patient developed multiple organ failure and, eventually, died. Lupus anticoagulant was revealed positive after the patient’s death, suggesting a catastrophic antiphospholipid syndrome. Clinical data and autopsy were consistent with this diagnosis.
How to Cite
Manzella, D., Vicente, L., Pérez de la Hoz, A., Zamora, R., De Rosa, G., & Pisarevsky, A. (2019). Catastrophic antiphospholipid syndrome as a complication of systemic sclerosis. Reumatismo, 71(2), 92–98. https://doi.org/10.4081/reumatismo.2019.1095
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- L. Andreoli, C. Nalli, M. Motta, G.L. Norman, W.L. Binder, M. Nuzzo, M. Frassi, A. Lojacono, T. Avcin, P.L. Meroni, A. Tincani, Subpopulations of anti-β2glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β2glycoprotein I , Reumatismo: Vol. 62 No. 3 (2010)
- G. Adami, A. Giollo, A. Fassio, C. Benini, E. Bertoldo, F. Bertoldo, G. Orsolini, L. Idolazzi, O. Viapiana, S. Giannini, G. Passeri, E. Tacconelli, C. Micheletto, D. Gatti, M. Rossini, Vitamin D and disease severity in coronavirus disease 19 (COVID-19) , Reumatismo: Vol. 72 No. 4 (2020)
- D.G. Fernández-Ávila, Ó.R. Vargas-Vanegas, L. Galindo-Rozo, Á. García-Peña, Ó. Muñoz-Velandia, Clinical characteristics and outcomes of patients with inflammatory and autoimmune rheumatological diseases admitted for intensive care in Colombia , Reumatismo: Vol. 75 No. 3 (2023)
- A. Ariani, L. Bazzichi, P. Sarzi-Puttini, F. Salaffi, M. Manara, I. Prevete, A. Bortoluzzi, G. Carrara, C.A. Scirè, N. Ughi, S. Parisi, The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia. Best practices based on current scientific evidence , Reumatismo: Vol. 73 No. 2 (2021)
- M. Govoni, N. Rizzo, G. Castellino, M. Padovan, F. Trotta, Neuropsychiatric systemic lupus erythematosus: where are we now? , Reumatismo: Vol. 57 No. 4 (2005)
- M. Fabris, L. Quartuccio, V. De Re, G. Pozzato, C. Mazzaro, A. Tavoni, C. Ferri, S. Salvin, A. Lerussi, C. Fabro, S. Bombardieri, S. De Vita, Fibronectin gene polymorphisms and clinical manifestations of mixed cryoglobulinemic syndrome: increased risk of lymphoma associated to MspI DD and HaeIII AA genotypes , Reumatismo: Vol. 60 No. 1 (2008)
- A. Marino, T. Varisco, G. Quattrocchi, A. Amoroso, D. Beltrami, S. Venturiello, A. Ripamonti, A. Villa , M. Andreotti, M. Ciuffreda, R. Cimaz, Children with Kawasaki disease or Kawasaki-like syndrome (MIS-C/PIMS) at the time of COVID-19: are they all the same? Case series and literature review , Reumatismo: Vol. 73 No. 1 (2021)
- Leonardo Punzi, Mauro Galeazzi, Vittorio Modena, Stefano Bombardieri, The registry for the systemic autoinflammatory syndromes of the Italian Society of Rheumatology , Reumatismo: Vol. 58 No. 1 (2006)
- N. Franzolini, L. Quartuccio, G. De Marchi, S. De Vita, Efficacy of immunosoppressive therapy and steroid sparing effect in interstitial lung disease associated to antisynthetase syndrome , Reumatismo: Vol. 59 No. 3 (2007)
- R. El-Beheidy, A.M. Domouky, H. Zidan, Y.A. Amer, Serum KL-6 as predictive and prognostic marker of interstitial lung disease in childhood connective tissue diseases: a pilot study , Reumatismo: Vol. 73 No. 3 (2021)
<< < 17 18 19 20 21 22 23 24 25 26 > >>
You may also start an advanced similarity search for this article.
